TITLE

Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial

AUTHOR(S)
Empen, Klaus; Frost, Robert J. A.; Geiss, H. Christian; Otto, Carsten; Parhofer, Klaus G.
PUB. DATE
January 2003
SOURCE
Cardiovascular Diabetology;2003, Vol. 2, p17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Diabetic dyslipoproteinemia is characterized by hypertriglyceridemia, low HDL-cholesterol and often elevated LDL-cholesterol and is a strong risk factor for atherosclerosis. Adhesion molecule levels are elevated both in hyperlipoproteinemia and diabetes mellitus. It is unclear whether fibrate or statin therapy has more beneficial effects on adhesion molecule concentrations. Methods: Atorvastatin (10 mg/d) was compared to fenofibrate (200 mg/d) each for 6 weeks separated by a 6 week washout period in 11 patients (6 male, 5 female; 61.8 ± 8.2 years; body mass index 29.8 ± 3.1 kg/m²) with type 2 diabetes mellitus (HbA1c 7.3 ± 1.1 %) and mixed hyperlipoproteinemia using a randomized, cross-over design. Fasting blood glucose, HbA1c, lipid parameters, E-selectin, ICAM-1, VCAM-1, and fibrinogen concentrations were determined before and after each drug. Results: Glucose and HbA1c concentrations remained unchanged during the whole study period. LDL cholesterol was reduced during atorvastatin therapy, triglycerides were lowered more effectively with fenofibrate. Comparison of pre- and postreatment concentrations of E-selectin showed a reduction during atorvastatin (-7 %, p = 0.11) and fenofibrate (-10 %, p < 0.05) therapy. Atorvastatin treatment reduced VCAM-1 levels by 4% (p < 0.05), while VCAM-1 concentrations remained unchanged (+1%, ns) during fenofibate therapy. However, direct comparisons of posttreatment levels during both forms of therapy were not of statistical significance. ICAM-1 levels were not influenced by either form of therapy. Conclusions: In addition to the different beneficial effects on lipid metabolism, both drugs appear to lower adhesion molecule plasma concentrations in a different manner in patients with type 2 diabetes and mixed hyperlipoproteinemia. Our observations should be confirmed in a larger cohort of such patients.
ACCESSION #
28683664

 

Related Articles

  • Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria. Nellemann, Birgitte; Gormsen, Lars C.; Dollerup, Jens; Schmitz, Ole; Mogensen, Carl E.; Rasmussen, Lars M.; Nielsen, Søren // Diabetes Care;Dec2007, Vol. 30 Issue 12, p3122 

    The article offers information on the results of a study on the effect of simvastatin on osteoprotegerin (OPG) and adhesion molecules in type 2 diabetic patients at increased risk for cardiovascular disease (CVD) due to persistent microalbuminuria. It states that the findings may reflect a...

  • Air pollution and inflammation in type 2 diabetes: a mechanism for susceptibility. O'Neill, M. S.; Veves, A.; Sarnat, J. A.; A. Zanobetti; Gold, D. R.; Economides, P. A.; E. S. Horton; Schwartz, J. // Occupational & Environmental Medicine;Jun2007, Vol. 64 Issue 6, p373 

    Background: Particulate air pollution has been associated with several adverse cardiovascular health outcomes, and people with diabetes may be especially vulnerable. One potential pathway is inflammation and endothelial dysfunction-processes in which cell adhesion molecules and inflammatory...

  • ACCORD and type 2 diabetes. Elliott, William // Alternative Medicine Alert;May2010 Supplement, p1 

    The article discusses the findings of three Action to Control Cardiovascular Risk in Diabetics (ACCORD) trials among patients with type 2 diabetes. The first study found that intensive therapy, which targeted glycosylated hemoglobin (A1c) at < 6.0%, increased mortality rate and failed to reduce...

  • ISCHAEMIC HEART DISEASE. Gorog, Diana; Kapur, Akhil; Khan, Masood; Lindsay, Alistair; Sharp, Andrew // Heart;Mar2006, Vol. 92 Issue 3, p430 

    The article presents a collection of research studies on ischemic heart disease published in various periodicals. The use of rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction has been assessed. Researchers examine the effects of long-term fenofibrate therapy on...

  • Fenofibrate Does Not Prevent Coronary Events. Barry, Henry // American Family Physician;4/15/2006, Vol. 73 Issue 8, p1443 

    Discusses research on the effects of long-term fenofibrate therapy on cardiovascular events in patients with type 2 diabetes. Reference to a study by A. Keech et al, published in the November 26, 2005 issue of "The Lancet"; Overview of the study methodology; Interpretation of the study findings.

  • Aggressive lipid control fails to benefit type 2 diabetics. Campbell, Maude // Drug Topics;Jun2010, Vol. 154 Issue 6, p28 

    The article reports on the addition of fenofibrate to statin therapy can minimize cardiovascular events in patients with type 2 diabetes. It mentions that the combination lipid treatment can lower the risks of low density of lipoprotein (LDL) to patients with type 2 diabetes. According to...

  • Statin benefits outweigh risk of developing diabetes.  // Pulse;2/24/2010, Vol. 70 Issue 6, p11 

    The article explores the benefits of statins that outweigh the risk of developing type 2 diabetes.

  • 398 Effect of statins on the course of CHF in patients with type 2 diabetes mellitus.  // European Journal of Heart Failure. Supplements;Jun2005, Vol. 4 Issue 1, p88 

    An abstract of the article "Effect of Statins on the Course of CHF in Patients With Type 2 Diabetes Mellitus," by G. Arutyunov and A. Beituganov is presented.

  • Clinical briefs.  // New Zealand Doctor;3/10/2010, p24 

    This section offers clinical news briefs including the role of statins in raising the relative risk of developing type 2 diabetes by nine percent, the risk posed by paroxetine to women taking tamoxifen for breast cancer, and the role of aspirin in helping women with breast cancer survive.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics